Literature DB >> 33505918

Cancer Stemness: p53 at the Wheel.

Dishari Ghatak1, Damayanti Das Ghosh2, Susanta Roychoudhury2.   

Abstract

The tumor suppressor p53 maintains an equilibrium between self-renewal and differentiation to sustain a limited repertoire of stem cells for proper development and maintenance of tissue homeostasis. Inactivation of p53 disrupts this balance and promotes pluripotency and somatic cell reprogramming. A few reports in recent years have indicated that prevalent TP53 oncogenic gain-of-function (GOF) mutations further boosts the stemness properties of cancer cells. In this review, we discuss the role of wild type p53 in regulating pluripotency of normal stem cells and various mechanisms that control the balance between self-renewal and differentiation in embryonic and adult stem cells. We also highlight how inactivating and GOF mutations in p53 stimulate stemness in cancer cells. Further, we have explored the various mechanisms of mutant p53-driven cancer stemness, particularly emphasizing on the non-coding RNA mediated epigenetic regulation. We have also analyzed the association of cancer stemness with other crucial gain-of-function properties of mutant p53 such as epithelial to mesenchymal transition phenotypes and chemoresistance to understand how activation of one affects the other. Given the critical role of cancer stem-like cells in tumor maintenance, cancer progression, and therapy resistance of mutant p53 tumors, targeting them might improve therapeutic efficacy in human cancers with TP53 mutations.
Copyright © 2021 Ghatak, Das Ghosh and Roychoudhury.

Entities:  

Keywords:  GOF mutant p53; cancer stemness; chemoresistance; differentiation; epithelial to mesenchymal transition; miRNAs; therapeutic targeting

Year:  2021        PMID: 33505918      PMCID: PMC7830093          DOI: 10.3389/fonc.2020.604124

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  263 in total

1.  Two supporting factors greatly improve the efficiency of human iPSC generation.

Authors:  Yang Zhao; Xiaolei Yin; Han Qin; Fangfang Zhu; Haisong Liu; Weifeng Yang; Qiang Zhang; Chengang Xiang; Pingping Hou; Zhihua Song; Yanxia Liu; Jun Yong; Pengbo Zhang; Jun Cai; Meng Liu; Honggang Li; Yanqin Li; Xiuxia Qu; Kai Cui; Weiqi Zhang; Tingting Xiang; Yetao Wu; Yiding Zhao; Chun Liu; Chen Yu; Kehu Yuan; Jinning Lou; Mingxiao Ding; Hongkui Deng
Journal:  Cell Stem Cell       Date:  2008-11-06       Impact factor: 24.633

Review 2.  Cancer stem cells and angiogenesis.

Authors:  Yue Zhao; Qi Bao; Andrea Renner; Peter Camaj; Martin Eichhorn; Ivan Ischenko; Martin Angele; Axel Kleespies; Karl-Walter Jauch; Christiane Bruns
Journal:  Int J Dev Biol       Date:  2011       Impact factor: 2.203

3.  A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.

Authors:  C Gaiddon; M Lokshin; J Ahn; T Zhang; C Prives
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.

Authors:  Gu Xiao; Devon Lundine; George K Annor; Jorge Canar; Viola Ellison; Alla Polotskaia; Patrick L Donabedian; Thomas Reiner; Galina F Khramtsova; Olufunmilayo I Olopade; Alexander Mazo; Jill Bargonetti
Journal:  Cancer Res       Date:  2019-11-27       Impact factor: 12.701

5.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

6.  MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.

Authors:  S Donzelli; G Fontemaggi; F Fazi; S Di Agostino; F Padula; F Biagioni; P Muti; S Strano; G Blandino
Journal:  Cell Death Differ       Date:  2011-12-23       Impact factor: 15.828

7.  A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells.

Authors:  Kyoung-Hwa Lee; Mangmang Li; Aleksandra M Michalowski; Xinyue Zhang; Hongling Liao; Lingyi Chen; Yang Xu; Xiaolin Wu; Jing Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

Review 8.  New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Authors:  Giovanni Blandino; Silvia Di Agostino
Journal:  J Exp Clin Cancer Res       Date:  2018-02-15

9.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

10.  Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

Authors:  David S Hong; Yoon-Koo Kang; Mitesh Borad; Jasgit Sachdev; Samuel Ejadi; Ho Yeong Lim; Andrew J Brenner; Keunchil Park; Jae-Lyun Lee; Tae-You Kim; Sangjoon Shin; Carlos R Becerra; Gerald Falchook; Jay Stoudemire; Desiree Martin; Kevin Kelnar; Heidi Peltier; Vinicius Bonato; Andreas G Bader; Susan Smith; Sinil Kim; Vincent O'Neill; Muhammad S Beg
Journal:  Br J Cancer       Date:  2020-04-02       Impact factor: 7.640

View more
  11 in total

Review 1.  p73 isoforms meet evolution of metastasis.

Authors:  Stella Logotheti; Athanasia Pavlopoulou; Stephan Marquardt; Işıl Takan; Alexandros G Georgakilas; Thorsten Stiewe
Journal:  Cancer Metastasis Rev       Date:  2022-08-11       Impact factor: 9.237

2.  miR-509 inhibits cancer stemness properties in oral carcinomas via directly targeting PlK1.

Authors:  Ming-Yi Lu; Chih-Yuan Fang; Pei-Ling Hsieh; Yi-Wen Liao; Lo-Lin Tsai; Cheng-Chia Yu
Journal:  J Dent Sci       Date:  2021-10-08       Impact factor: 3.719

3.  Trp53 controls chondrogenesis and endochondral ossification by negative regulation of TAZ activity and stability via β-TrCP-mediated ubiquitination.

Authors:  Yang Li; Shu-Ting Yang; Shuying Yang
Journal:  Cell Death Discov       Date:  2022-07-12

Review 4.  p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance.

Authors:  Leonel Cardozo de Menezes E Souza; Anderson Faletti; Carla Pires Veríssimo; Mariana Paranhos Stelling; Helena Lobo Borges
Journal:  Membranes (Basel)       Date:  2022-02-09

5.  RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53.

Authors:  Xiangli Liu; Ziyi Wang; Qiwei Yang; Xiaohai Hu; Qiang Fu; Xinyu Zhang; Wenya Li
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

6.  WDR36 Safeguards Self-Renewal and Pluripotency of Human Extended Pluripotent Stem Cells.

Authors:  Shiyu An; Dan Yao; Wenyi Zhang; Hao Sun; Tianyi Yu; Ruizhe Jia; Yang Yang
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

7.  Differentially expression and function of circular RNAs in ovarian cancer stem cells.

Authors:  Eun Jung Sohn
Journal:  J Ovarian Res       Date:  2022-08-17       Impact factor: 5.506

8.  miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patients.

Authors:  Adriana Taveira da Cruz; Aline Hunger; Fabiana Henriques Machado de Melo; Ana Carolina Monteiro; Geneviève Catherine Paré; Dulce Lai; Débora Kristina Alves-Fernandes; Ana Luisa Pedroso Ayub; Esteban Mauricio Cordero; José Franco da Silveira Filho; Regine Schneider-Stock; Bryan Eric Strauss; Victor Tron; Miriam Galvonas Jasiulionis
Journal:  Neoplasia       Date:  2021-07-08       Impact factor: 5.715

9.  FOXD1 promotes EMT and cell stemness of oral squamous cell carcinoma by transcriptional activation of SNAI2.

Authors:  Yang Chen; Weilian Liang; Ke Liu; Zhengjun Shang
Journal:  Cell Biosci       Date:  2021-08-04       Impact factor: 7.133

Review 10.  Infection by High-Risk Human Papillomaviruses, Epithelial-to-Mesenchymal Transition and Squamous Pre-Malignant or Malignant Lesions of the Uterine Cervix: A Series of Chained Events?

Authors:  Giovanni Barillari; Roberto Bei; Vittorio Manzari; Andrea Modesti
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.